Treatment of Elderly Cancer Patients with Chemotherapy

References

• Yancik, R. Cancer burden in the aged: an epidemiologic and demographic overview.Cancer 1997, 80, 1273–1283. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Edward, B K.; Howe, H L.; Ries, L A.; Thun, M J.; Rosenberg, H M.; Yancik, R.; Wingo, P A.; Jemal, A.; Feigal, E G. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden.Cancer 2002, 94, 2766–2792. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lichtman, S M.; Skirvin, J A.; Vemulapalli, S. Pharmacology of antineoplastic agents in older cancer patients.Crit. Rev. Oncol./Hematol. 2003, 46, 101–114. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Repetto, L.; Biganzoli, L.; Koehne, C H.; Luebbe, A S.; Soubeyran, P.; Tjan-Heijan, V C.; Aapro, M S. Eortc cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer.Eur. J. Cancer 2003, 39, 2264–2272. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yee, K W.; Pater, J L.; Pho, L.; Zee, B.; Siu, L L. Enrollment of older patients in cancer treatment trials in canada: why is age a barrier?. J. Clin. Oncol. 2003, 21, 1618–1623. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• John, V.; Mashru, S.; Lichtman, S. Pharmacological factors influencing anticancer drug selection in the elderly.Drugs Aging 2003, 20, 737–759. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Extermann, M.; Chen, H.; Cantor, A B.; Corcoran, M B.; Meyer, J.; Grendys, E.; Cavanaugh, D.; Antonek, S.; Camarata, A.; Haley, W E.; Balducci, L. Predictors of tolerance to chemotherapy in older cancer patients. A prospective pilot study.Eur. J. Cancer 2002, 38, 1466–1473. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Extermann, M. Assessing elderly cancer patients. The SIOG task force on oncogeriatric assessment presents its findings to the experts.Cancer Futures 2003, 2, 155–157. [CSA]
   Google Scholar
• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's Lymphoma Prognostic Factors Project.N. Engl. J. Med. 1993, 329, 987–994., [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nixon, A J.; Neuberg, D.; Hayes, D F.; Gelman, R.; Connolly, J L.; Schnitt, S.; Abner, A.; Recht, A.; Vicini, F.; Harris, J R. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.J. Clin. Oncol. 1994, 12, 888–894. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kimmick, G G.; Balducci, L. Breast cancer and aging. Clinical interactions.Hematol./Oncol. Clin. North Am. 2000, 14, 213–234. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stone, R M.; Berg, D T.; George, S L.; Dodge, R K.; Paciucci, P A.; Schulman, P.; Lee, E J.; Moore, J O.; Powell, B L.; Schiffer, C A. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group B.N. Engl. J. Med. 1995, 332, 1671–1677. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Leith, C P.; Kopecky, K J.; Godwin, J.; McConnell, T.; Slovak, M L.; Chen, I M.; Head, D R.; Appelbaum, F R.; Willman, C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.Blood 1997, 89, 3323–3329. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Preti, H A.; Cabanillas, F.; Talpaz, M.; Tucker, S L.; Seymour, J F.; Kurzrock, R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.Ann. Intern. Med. 1997, 127, 186–194. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lipschitz, D A. Aging of the hematopoietic system. In Principles of Geriatric Medicine and Gerontology; Hazzard, W R., Bierman, E L., Blass, J P., Eds.; McGraw-Hill: New York, 1994; 733–739.
   Google Scholar
• Dees, E C.; O'Reilly, S.; Goodman, S N.; Sartorius, S.; Levine, M A.; Jones, R J.; Grochow, L B.; Donehower, R C.; Fetting, J H. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.Cancer Investig. 2000, 18, 521–529. [CSA]
   PubMed Web of Science ®Google Scholar
• Gomez, H.; Mas, L.; Casanova, L.; Pen, D L.; Santillana, S.; Valdivia, S.; Otero, J.; Rodriguez, W.; Carracedo, C.; Vallejos, C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with chop chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.J. Clin. Oncol. 1998, 16, 2352–2358. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schild, S E.; Stella, P J.; Geyer, S M.; Bonner, J A.; McGinnis, W L.; Mailliard, J A.; Brindle, J.; Jatoi, A.; Jett, J R. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.J. Clin. Oncol. 2003, 21, 3201–3206. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Balducci, L.; Lyman, G H. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.J. Clin. Oncol. 2001, 19, 1583–1585. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Balducci, L.; Yates, J. General guidelines for the management of older patients with cancer.Oncology (Huntingt.) 2000, 14, 221–227. [CSA]
   PubMed Web of Science ®Google Scholar
• Balducci, L.; Repetto, L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma.Cancer 2004, 100, 6–11. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morrison, V.; Weller, E.; Habermann, T.; Li, S.; Horning, S J.; Fisher, R I.; Peterson, B A. Patterns of growth factor (gf) usage and febrile neutropenia (fn) among older patients (pts) with diffuse large B-cell lymphoma (dlbcl) treated with chop or r-chop: an intergroup experience (calgb 9793, ecog-swog 4494).Blood (ASH Abstracts) 2004; 104: 3309a. [CSA]
   Google Scholar
• Lyman, G H.; Dale, D C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.J. Clin. Oncol. 2003, 21, 4524–4531. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hutchins, L F.; Unger, J M.; Crowley, J J.; Coltman, C A., Jr.; Albain, K S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials.N. Engl. J. Med. 1999, 341, 2061–2067. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baker, S D.; Grochow, L B. Pharmacology of cancer chemotherapy in the older person.Clin. Geriatr. Med. 1997, 13, 169–183. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• DeMario, M D.; Ratain, M J. Oral chemotherapy: rationale and future directions.J. Clin. Oncol. 1998, 16, 2557–2567. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Richardson, J L.; Shelton, D R.; Krailo, M.; Levine, A M. The effect of compliance with treatment on survival among patients with hematologic malignancies.J. Clin. Oncol. 1990, 8, 356–364. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lebovits, A H.; Strain, J J.; Schleifer, S J.; Tanaka, J S.; Bhardwaj, S.; Messe, M R. Patient noncompliance with self-administered chemotherapy.Cancer 1990, 65, 17–22. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kastrissios, H.; Blaschke, T F. Medication compliance as a feature in drug development.Annu. Rev. Pharmacol. Toxicol. 1997, 37, 451–475. [PUBMED], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Urquhart, J. Patient compliance with crucial drug regimens: implications for prostate cancer.Eur. Urol. 1996, 29, 124–131. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Egorin, M J. Cancer pharmacology in the elderly.Semin. Oncol. 1993, 20, 43–49. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schrijvers, D.; Highley, M.; De Bruyn, E.; Van Oosterom, A T.; Vermorken, J B. Role of red blood cells in pharmacokinetics of chemotherapeutic agents.Anti-Cancer Drugs 1999, 10, 147–153. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Evans, W E.; McLeod, H L. Pharmacogenomics—drug disposition, drug targets, and side effects.N. Engl. J. Med. 2003, 348, 538–549. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Flockhart, D. Cytochrome p450 drug interaction table. 2002, Available online at: http://medicineiupuiedu/flockhart/. [CSA]
   Google Scholar
• Flockhart, D A.; Tanus-Santos, J E. Implications of cytochrome p450 interactions when prescribing medication for hypertension.Arch. Intern. Med. 2002, 162, 405–412. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Flockhart, D A.; Rae, J M. Cytochrome p450 3a pharmacogenetics: the road that needs traveled.Pharmacogenomics J. 2003, 3, 3–5. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sotanieme, E A.; Arranto, A J.; Pelkonen, O.; Psanen, M. Age and cytochrome p450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.Clin. Pharmacol. Ther. 1997, 61, 331–339. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brenner, B M.; Meyer, G W.; Hostetter, T H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.N. Engl. J. Med. 1982, 307, 652–659. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Swedko, P J.; Clark, H D.; Paramsothy, K.; Akbari, A. Serum creatinine is an inadequate screening test for renal failure in elderly patients.Arch. Intern. Med. 2003, 163, 356–360. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cockcroft, D W.; Gault, M H. Prediction of creatinine clearance from serum creatinine.Nephron 1976, 16, 31–41. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jelliffe, R W. Estimation of creatinine clearance when urine cannot be collected.Lancet 1971, 1, 975–976. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marx, G M.; Blake, G M.; Galani, E.; Steer, C B.; Harper, S E.; Adamson, K L.; Bailey, D L.; Harper, P G. Evaluation of the cockroft-gault, jelliffe and wright formulae in estimating renal function in elderly cancer patients.Ann. Oncol. 2004, 15, 291–295. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kintzel, P E.; Dorr, R T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.Cancer Treat. Rev. 1995, 21, 33–64. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Charlson, M E.; Pompei, P.; Ales, K L.; MacKenzie, C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J. Chronic. Dis. 1987, 40, 373–383. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Yancik, R.; Wesley, M N.; Ries, L A.; Havlik, R J.; Long, S.; Edwards, B K.; Yates, J W. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study.Cancer 1998, 82, 2123–2134. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Satariano, W A.; Ragland, D A. The effect of comorbidity on 3-year survival of women with primary breast cancer.Ann. Intern. Med. 1994, 120, 104–110. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Extermann, M.; Overcash, J.; Lyman, G H.; Parr, J.; Balducci, L. Comorbidity and functional status are independent in older cancer patients.J. Clin. Oncol. 1998, 16, 1582–1587. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rockwood, K.; Stadnyk, K.; MacKnight, C.; McDowell, I.; Hebert, R.; Hogan, D B. A brief clinical instrument to classify frailty in elderly people.Lancet 1999, 353, 205–206., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lunney, J R.; Lynn, J.; Hogan, C. Profiles of older medicare decedents.J. Am. Geriatr. Soc. 2002, 50, 1108–1112. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Repetto, L.; Comandini, D.; Mammoliti, S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients.Crit. Rev. Oncol./Hematol. 2001, 37, 147–152. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fried, L P.; Tangen, C M.; Watson, J.; Newman, A B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W J.; Burke, G.; McBurnie, M A. Frailty in older adults: evidence for a phenotype.J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 2001, 56, M146–M156. [CSA]
   PubMed Web of Science ®Google Scholar
• Balducci, L.; Stanta, G. Cancer in the frail patient. A coming epidemic.Hematol./Oncol. Clin. North Am. 2000, 14, 235–250. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamerman, D. Toward an understanding of frailty.Ann. Intern. Med. 1999, 130, 945–950. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cohen, H J.; Feussner, J R.; Weinberger, M.; , et al. A controlled trial of inpatient and outpatient geriatric evaluation and management.N. Engl. J. Med. 2002, 346, 905–912. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ingram, S S.; Seo, P H.; Martell, R E.; Clipp, E C.; Doyle, M E.; Montana, G S.; Cohen, H J. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology.J. Clin. Oncol. 2002, 20, 770–775. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Repetto, L.; Fratino, L.; Audisio, R A.; Venturino, A.; Gianni, W.; Vercelli, M.; Parodi, S.; Dal Lago, D.; Gioia, F.; Monfardini, S.; Aapro, M S.; Serraino, D.; Zagonel, V. Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study.J. Clin. Oncol. 2002, 20, 494–502. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monfardini, S.; Ferrucci, L.; Fratino, L.; del Lungo, I.; Serraino, D.; Zagonel, V. Validation of a multidimensional evaluation scale for use in elderly cancer patients.Cancer 1996, 77, 395–401. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bogg, D R.; Patrene, K D. Hematopoiesis and aging III: anemia and a blunted erythropoietic response to hemorrhage in aged mice.Am. J. Hematol. 1985, 19, 327–338. [CSA]
   PubMed Web of Science ®Google Scholar
• Rothstein, G.; Christensen, R D.; Nielsen, B R. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice.Blood 1987, 70, 1836–1841. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baraldi-Junkins, C A.; Beck, A C.; Rothstein, G. Hematopoiesis and cytokines. Relevance to cancer and aging.Hematol./Oncol. Clin. North Am. 2000, 14, pp. 45–61, viii. [CSA]
   PubMed Web of Science ®Google Scholar
• Ania, B J.; Suman, V J.; Fairbanks, V F.; Rademacher, D M.; Melton, L J., III. Incidence of anemia in older people: an epidemiologic study in a well defined population.J. Am. Geriatr. Soc. 1997, 45, 825–831. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chaves, P H.; Ashar, B.; Guralnik, J M.; Fried, L P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?. J. Am. Geriatr. Soc. 2002, 50, 1257–1264. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ania, B J.; Suman, V J.; Fairbanks, V F.; Melton, L J., III. Prevalence of anemia in medical practice: community versus referral patients.Mayo Clin. Proc. 1994, 69, 730–735. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Crawford, J.; Dale, D C.; Lyman, G H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.Cancer 2004, 100, 228–237. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schild, S E.; Stella, P J.; Geyer, S M.; Bonner, J A.; McGinnis, W L.; Mailliard, J A.; Brindle, J.; Jatoi, A.; Jett, J R. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.J. Clin. Oncol. 2003, 21, 3201–3206. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Argiris, A.; Li, Y.; Murphy, B A.; Langer, C J.; Forastiere, A A. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.J. Clin. Oncol. 2004, 22, 262–268. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lyman, G H.; Delgado, D J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.Cancer 2003, 98, 2402–2409. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lyman, G H.; Dale, D C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.J. Clin. Oncol. 2003, 21, 4524–4531. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonadonna, G.; Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer.N. Engl. J. Med. 1981, 304, 101–105. [CSA]
   Google Scholar
• Chrischilles, E A.; Link, B K.; Scott, S D.; Delgado, D J.; Fridman, M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma.Cancer Control 2003, 10, 396–403. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Dixon, D O.; Neilan, B.; Jones, S.; Lipschitz, D A.; Miller, T P.; Grozea, P N.; Wilson, H E, et al. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience.J. Clin. Oncol. 1986, 4, 295–305. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Muss, H.; Woolf, S.; Berry, D.; Weiss, R.; Budman, D.; Wood, W.; Henderson, C.; Hudis, C.; Norton, L. Older women with node positive (n + ) breast cancer (bc) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): the cancer and leukemia group B (calgb) experience.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 11a. [CSA]
   PubMedGoogle Scholar
• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials.Lancet 1998, 352, 930–942. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hurria, A.; Leung, D.; Trainor, K.; Borgen, P.; Norton, L.; Hudis, C. Factors influencing treatment patterns of breast cancer patients age 75 and older.Crit. Rev. Oncol./Hematol. 2003, 46, 121–126. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hughes, K S.; Schnaper, L.; Berry, D.; , et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (rt) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (er + ) breast carcinoma.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2001, 20, 93a. [CSA]
   Google Scholar
• Budman, D R.; Berry, D A.; Cirrincione, C T.; Henderson, I C.; Wood, W C.; Weiss, R B.; Ferree, C R.; Muss, H B.; Green, M R.; Norton, L.; Frei, E. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B.J. Natl. Cancer Inst. 1998, 90, 1205–1211. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Crivellari, D.; Bonetti, M.; Castiglione-Gertsch, M.; Gelber, R D.; Rudenstam, C M.; Thurlimann, B.; Price, K N.; Coates, A S.; Hurny, C.; Bernhard, J.; Lindtner, J.; Collins, J.; Senn, H J.; Cavalli, F.; Forbes, J.; Gudgeon, A.; Simoncini, E.; Cortes-Funes, H.; Veronesi, A.; Fey, M.; Goldhirsch, A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group trial VII.J. Clin. Oncol. 2000, 18, 1412–1422. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lichtman, S M.; Zaheer, W.; Gal, D.; Lovecchio, J.; DeMarco, L C.; Schulman, P.; Budman, D R.; Taibbi, R.; Fenton, C.; Vinciguerra, V. No increased risk of taxol toxicity in older patients.J. Am. Geriatr. Soc. 1996, 44, 472–474. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Del Mastro, L.; Perrone, F.; Repetto, L.; Manzione, L.; Zagonel, V.; Fratino, L.; Marenco, D.; Venturini, M.; Maggi, E.; Bighin, C.; Catzeddu, T.; Venturino, A.; Rosso, R. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGER).Ann. Oncol. 2005, 16, 253–258. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Citron, M L.; Berry, D A.; Cirrincione, C.; Hudis, C.; Winer, E P.; Gradishar, W J.; Davidson, N E.; Martino, S.; Livingston, R.; Ingle, J N.; Perez, E A.; Carpenter, J.; Hurd, D.; Holland, J F.; Smith, B L.; Sartor, C I.; Leung, E H.; Abrams, J.; Schilsky, R L.; Muss, H B.; Norton, L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/cancer and leukemia group B trial 9741.J. Clin. Oncol. 2003, 21, 1431–1439., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Buzdar, A U. ‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer—efficacy overview.J. Steroid Biochem. Mol. Biol. 2003, 86, 399–403. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Klijn, J.; for the ATAC Trialists' Group. The ATAC (anastrozole, tamoxifen, alone or in combination) trial. An efficacy update, focusing on breast cancer (bc) events, based on a median follow-up of 47 months.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 338a. [CSA]
   Google Scholar
• Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J F.; Hoctin-Boes, G.; Houghton, J.; Locker, G Y.; Tobias, J S. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer.Lancet 2005, 365, 60–62. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goss, P E.; Ingle, J N.; Martino, S.; Robert, N J.; Muss, H B.; Piccart, M J.; Castiglione, M.; Tu, D.; Shepherd, L E.; Pritchard, K I.; Livingston, R B.; Davidson, N E.; Norton, L.; Perez, E A.; Abrams, J S.; Therasse, P.; Palmer, M J.; Pater, J L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N. Engl. J. Med. 2003; 349, 1793–1802. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nabholtz, J M.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.; Mangalik, A.; Steinberg, M.; Webster, A.; von Euler, M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.J. Clin. Oncol. 2000, 18, 3758–3767. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H P.; Janicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P P.; Salminen, E.; Snyder, R.; Lassus, M.; Verbeek, J A.; Staffler, B.; Chaudri-Ross, H A.; Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.J. Clin. Oncol. 2001, 19, 2596–2606. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel, C.; Cobleigh, M A.; Tripathy, D.; Gutheil, J C.; Harris, L N.; Fehrenbacher, L.; Slamon, D J.; Murphy, M.; Novotny, W F.; Burchmore, M.; Shak, S.; Stewart, S J. First-line, single-agent herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.Eur. J. Cancer 2001, 37 (Suppl. 1), S25–S29. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Slamon, D J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med. 2001, 344, 783–792. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burstein, H.; Kuter, I.; Campos, S.; Gelman, R.; Tribou, L.; Parker, L.; Manola, J.; Younger, J.; Matulonis, U.; Bunnell, C.; Partridge, A.; Richardson, P.; Clarke, K.; Shulman, L.; Winer, E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J. Clin. Oncol. 2001, 19, 2722–2730. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sledge, G W., Jr. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.Semin. Oncol. 2003, 30, 19–21. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy, J A. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.Ann. Oncol. 2002, 13, 983. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy, J A.; Blum, J.; Moiseyenko, V.; Jones, S E.; Miles, D.; Bell, D.; Rosso, R.; Mauriac, L.; Osterwalder, B.; Burger, H U.; Laws, S. Randomized, open-label, phase II trial of oral capecitabine (xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.Ann. Oncol. 2001, 12, 1247–1254. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seidman, A D.; Berry, D.; Cirrincione, C.; Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J F.; Hoctin-Boes, G.; Houghton, J.; Locker, G Y.; Tobias, J S. Calgb 9840: phase III study of weekly (w) paclitaxel (p) vita 1-hour(h) infusion versus standard (s) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (t) for HER2 positive MBC and randomized for t in HER2 normal MBC.J. Clin. Oncol. (Meeting Abstracts) 2004, 22, 512. [CSA]
   Google Scholar
• Perez, E A.; Vogel, C L.; Irwin, D H.; Kirshner, J J.; Patel, R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.J. Clin. Oncol. 2001, 19, 4216–4223. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sundararajan, V.; Grann, V R.; Jacobson, J S.; Ahsan, H.; Neugut, A I. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study.Cancer J. 2001, 7, 213–218. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sundararajan, V.; Mitra, N.; Jacobson, J S.; Grann, V R.; Heitjan, D F.; Neugut, A I. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.Ann. Intern. Med. 2002, 136, 349–357. [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Neugut, A I.; Fleischauer, A T.; Sundararajan, V.; Mitra, N.; Heitjan, D F.; Jacobson, J S.; Grann, V R. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study.J. Clin. Oncol. 2002, 20, 2643–2650. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sargen, D J.; Goldberg, R M.; Jacobson, S D.; , et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.N. Engl. J. Med. 2001, 345, 1091–1097. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stein, B N.; Petrelli, N J.; Douglas, H O.; Driscoll, D L.; Arcangeli, G.; Meropol, N J. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.Cancer 1995, 75, 11–17. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chiara, S.; Nobile, M T.; Vincenti, M.; Lionetto, R.; Gozza, A.; Barzacchi, M C.; Sanguineti, O.; Repetto, L.; Rosso, R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.Cancer Chemother. Pharmacol. 1998, 42, 336–340. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Gramont, A.; Banzi, M.; Navarro, M.; , et al. Oxaliplatin/5-fu/lv in adjuvant colon cancer: results of the International Randomized MOSAIC trial.Proc. Ann. Meet. Am. Assoc. Cancer Res. 2003, 22, 1015a. [CSA]
   Google Scholar
• Tabah-Fisch, I.; Maindrault-Goebel, F.; Benavides, M.; , et al. Oxaliplatin/5fu/lv is feasible, safe and active in elderly colorectal cancer (CRC) patients.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2002, 21, 556a. [CSA]
   Google Scholar
• Carreca, I.; Comella, P.; Maiorino, L.; , et al. Oral capecitabine plus oxaliplatin (xelox regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) phase II study.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003; 22: 2939a. [CSA]
   Google Scholar
• Aparicio, T.; Desrame, J.; Lecomte, T.; Mitry, E.; Belloc, J.; Etienney, I.; Montembault, S.; Vayre, L.; Locher, C.; Ezenfis, J.; Artru, P.; Mabro, M.; Dominguez, S. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.Br. J. Cancer 2003, 89, 1439–1444. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Douillard, J Y.; Sobrero, A.; Carnaghi, C.; Comella, P.; Diaz-Rubio, E.; Santoro, A.; Van Cutsem, E. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.Ann. Oncol. 2003, 14 (Suppl. 2), ii7–ii12. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tournigand, C.; Andre, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. Folfiri followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J. Clin. Oncol. 2004, 22, 229–237. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldberg, R M.; Sargent, D J.; Morton, R F.; Fuchs, C S.; Ramanathan, R K.; Williamson, S K.; Findlay, B P.; Pitot, H C.; Alberts, S R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J. Clin. Oncol. 2004, 22, 23–30. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Takimoto, C H.; Remick, S C.; Sharma, S.; Mani, S.; Ramanathan, R K.; Doroshow, J H.; Hamilton, A.; Mulkerin, D.; Graham, M.; Lockwood, G F.; Ivy, P.; Egorin, M.; Greenslade, D.; Goetz, A.; Grem, J L. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.Semin. Oncol. 2003, 30, 20–25. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Saltz, L B.; Cox, J V.; Blanke, C.; Rosen, L S.; Fehrenbacher, L.; Moore, M J.; Maroun, J A.; Ackland, S P.; Locker, P K.; Pirotta, N.; Elfring, G L.; Miller, L L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group.N. Engl. J. Med. 2000, 343, 905–914. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Venook, A P.; Enders Klein, C.; Fleming, G.; Hollis, D.; Leichman, C G.; Hohl, R.; Byrd, J.; Budman, D.; Villalona, M.; Marshall, J.; Rosner, G L.; Ramirez, J.; Kastrissios, H.; Ratain, M J. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.Ann. Oncol. 2003, 14, 1783–1790. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rothenberg, M L.; Berlin, J D. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?. J. Clin. Oncol. 2003, 21, 3716–3717. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rothenberg, M L.; Oza, A M.; Bigelow, R H.; Berlin, J D.; Marshall, J L.; Ramanathan, R K.; Hart, L L.; Gupta, S.; Garay, C A.; Burger, B G.; Le Bail, N.; Haller, D G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.J. Clin. Oncol. 2003, 21, 2059–2069. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hurwitz, H.; Fehrenbacher, L.; Cartwright, T.; Hainsworth, J.; , et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 3646a. [CSA]
   Google Scholar
• Hoff, P M.; Ansari, R.; Batist, G.; Cox, J.; Kocha, W.; Kuperminc, M.; Maroun, J.; Walde, D.; Weaver, C.; Harrison, E.; Burger, H U.; Osterwalder, B.; Wong, A O.; Wong, R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.J. Clin. Oncol. 2001, 19, 2282–2292. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E.; Twelves, C.; Tabemero, J.; , et al. Xelox: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer.Proc. Ann. Meet. Am. Assoc. Cancer Res. 2003, 22, 1023a. [CSA]
   Google Scholar
• Bollina, R.; Beretta, G.; Toniolo, D.; Cozzi, C.; , et al. Capecitabine (c) and irinotecan (i) (CAPIRI): a good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (ct). Preliminary results of a phase II trial.Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 1332a. [CSA]
   Google Scholar
• Szatrowski, T P. Correspondence from Roche Laboratories, Inc.; 2000.
   Google Scholar
• Cunningham, D.; Humblet, Y.; Siena, S.; , et al. Cetuximab (c225) alone or in combination with irinotecan (cpt-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 1012a. [CSA]
   Google Scholar
• Salomon, D S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev. Oncol./Hematol. 1995, 19, 183–232. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Messa, C.; Russo, F.; Caruso, M G.; Di Leo, A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.Acta Oncol. 1998, 37, 285–289. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mayer, A.; Takimoto, M.; Fritz, E.; Schellander, G.; Kofler, K.; Ludwig, H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer.Cancer 1993, 71, 2454–2460. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Salt, L B.; Meropol, N J.; Loehrer, P J., Sr.; Needle, M N.; Kopit, J.; Mayer, R J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor if already been published.].J. Clin. Oncol. 2004, 22, 1201–1208. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fisher, R I.; Gaynor, E R.; Dahlberg, S.; Oken, M M.; Grogen, T M.; Mize, E M.; Glick, J H.; Coltman, C A.J.; Miller, T P. Comparison of a standard regimen (chop) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N. Engl. J. Med. 1993, 328, 1002–1006. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kouroukis, C T.; Browman, G P.; Esmail, R.; Meyer, R M. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review.Ann. Intern. Med. 2002, 136, 136–143. [CSA]
   PubMedGoogle Scholar
• Lichtman, S M. Aggressive lymphoma in the elderly.Crit. Rev. Oncol./Hematol. 2000, 33, 119–128. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human antibodies for therapy.Nature 1988, 332, 323–327. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McLaughlin, P.; Grillo-Lopez, A J.; Link, B K.; Levy, R.; Czuczman, M S.; Williams, M E.; Heyman, M R.; Bence-Bruckler, I.; White, C A.; Cabanillas, F.; Jain, V.; Ho, A D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B K. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J. Clin. Oncol. 1998, 16, 2825–2833. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Lederlin, P.; Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N. Engl. J. Med. 2002, 346, 235–242. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Habermann, T.; Weller, E.; Morrison, V A.; Cassileth, P A.; Cohn, J.; Dakhil, S.; Gascoyne, R D.; Woda, B.; Fisher, R.; Peterson, B A.; Horning, S J. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update.Blood (ASH Abstracts) 2004; 104: 127a. [CSA]
   Google Scholar
• Pfreundschul, M.; Truemper, L.; Kloes, M.; , et al. 2-Weekly vs. 3-weekly CHOP with and without etoposide for patients > 60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-b-2 trial of the DSHNHL.Blood 2002, 99 (Suppl. 1), 3060a. [CSA]
   PubMedGoogle Scholar
• Sundararajan, V.; Hershman, D.; Grann, V R.; Jacobson, J S.; Neugut, A I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.J. Clin. Oncol. 2002, 20, 173–178. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McGuire, W P.; Hoskins, W J.; Brady, M F.; Kucera, P R.; Partridge, E E.; Look, K Y.; Clarke-Pearson, D L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N. Engl. J. Med. 1996, 334, 1–6. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neijt, J P.; Engelholm, S A.; Tuxen, M K.; Sorensen, P G.; Hansen, M.; Sessa, C.; de Swart, C A.; Hirsch, F R.; Lund, B.; van Houwelingen, H C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.J. Clin. Oncol. 2000, 18, 3084–3092. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Langer, C J.; Manola, J.; Bernard, P.; Kugler, J W.; Bonomi, P.; Cella, D.; Johnson, D H. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.J. Natl. Cancer Inst. 2002, 94, 173–181. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lichtman, S M.; Buchholtz, M.; Marino, J.; Schulman, P.; Allen, S L.; Weiselberg, L.; Budman, D.; DeMarco, L.; Schuster, M.; Lovecchio, J; , et al. Use of cisplatin for elderly patients.Age Ageing 1992, 21, 202–204. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Calvert, A H.; Newell, D R.; Gumbrell, L A.; S, O R.; Burnell, M.; Boxall, F E.; Siddik, Z H.; Judson, I R.; Gore, M E.; Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.J. Clin. Oncol. 1989, 7, 1748–1756. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ozols, R F. Optimum chemotherapy for ovarian cancer.Int. J. Gynecol. Cancer 2000, 10, 33–37. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gronlund, B.; Hogdall, C.; Hansen, H H.; Engelholm, S A. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.Cancer 2002, 94, 1961–1967. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dizon, D S.; Hensley, M L.; Poynor, E A.; , et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.J. Clin. Oncol. 2002, 20, 1238–1247. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ozols, R F. Recurrent ovarian cancer: evidence-based treatment.J. Clin. Oncol. 2002, 20, 1161–1163. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hainsworth, J D.; Burris, H A., III; Litchy, S.; Morrissey, L H.; Barton, J H.; Bradof, J E.; Greco, F A. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial.Cancer 2000, 89, 328–333. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perez, E A.; Vogel, C L.; Irwin, D H.; Kirshner, J J.; Patel, R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer.Breast Cancer Res. Treat. 2002, 73, 85–88. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Homesley, H D.; Hall, D J.; Martin, D A.; Lewandowski, G S.; Vaccarello, L.; Nahhas, W A.; Suggs, C L.; Penley, R G. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.Gynecol. Oncol. 2001, 83, 394–399. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Armstrong, D K. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.Oncologist 2004, 9, 33–42. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seymour, M T.; Mansi, J L.; Gallagher, C J.; Gore, M E.; Harper, P G.; Evans, T R.; Edmonds, P M.; Slevin, M L. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.Br. J. Cancer 1994, 69, 191–195. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rocha Lima, C.; Herndon, J.; Kosty, M.; Clamon, G.; Green, M. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the cancer and leukemia group B.Cancer 2002, 94, 181–187. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hensing, T A.; Peterman, A H.; Schell, M J.; Lee, J H.; Socinski, M A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.Cancer 2003, 98, 779–788. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sequist, L V.; Lynch, T J. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!.J. Clin. Oncol. 2003, 3186–3188. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gridelli, C.; Perrone, F.; Gallo, C.; De Marinis, F.; Ianniello, G.; Cigolari, S.; Cariello, S.; Di Costanzo, F.; M, D A.; Rossi, A.; Migliorino, R.; Bartolucci, R.; Bianco, A R.; Pergola, M.; Monfardini, S. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study.Eur. J. Cancer 1997, 33, 392–397. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gridelli, C.; Perrone, F.; Gallo, C.; Cigolari, S.; Rossi, A.; Piantedosi, F.; Barbera, S.; Ferrau, F.; Piazza, E.; Rosetti, F.; Clerici, M.; Bertetto, O.; Robbiati, S F.; Frontini, L.; Sacco, C.; Castiglione, F.; Favaretto, A.; Novello, S.; Migliorino, M R.; Gasparini, G.; Galetta, D.; Iaffaioli, R V.; Gebbia, V. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (Miles) phase III randomized trial.J. Natl. Cancer Inst. 2003, 95, 362–372. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lilenbaum, R. Management of advanced non-small-cell lung cancer in patients with a performance status of 2.Clin. Lung Cancer 2004, 5, 209–213. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lilenbaum, R. Management of advanced non-small-cell lung cancer in elderly populations.Clin. Lung Cancer 2003, 5, 169–173. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Schiller, J H.; Harrington, D.; Belani, C P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N. Engl. J. Med. 2002, 346, 92–98. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shepherd, F A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; Coughlin, S.; Kim, Y.; Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.J. Clin. Oncol. 2000, 18, 2095–2103. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Johnson, D H.; Arteaga, C L. Gefitinib in recurrent non-small-cell lung cancer: an ideal trial?. J. Clin. Oncol. 2003, 21, 2227–2229. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cappuzzo, F.; Gregorc, V.; Rossi, E.; Cancellieri, A.; Magrini, E.; Paties, C T.; Ceresoli, G.; Lombardo, L.; Bartolini, S.; Calandri, C.; De Rosa, M.; Villa, E.; Crino, L. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.J. Clin. Oncol. 2003, 21, 2658–2663. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.N. Engl. J. Med. 2004, 350, 351–360. [CSA]
   PubMed Web of Science ®Google Scholar